[A02BX02, sucralfate, Sucralfate can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01EC01, sulfamethoxazole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Sulfamethoxazole is combined with Raltegravir.]
[N06DA01, tacrine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrine is combined with Raltegravir.]
[S01BA05, triamcinolone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Triamcinolone is combined with Raltegravir.]
[N05CD05, triazolam, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Triazolam is combined with Raltegravir.]
[J01EA01, trimethoprim, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Raltegravir.]
[L01CA02, vincristine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Vincristine is combined with Raltegravir.]
[S01AA13, fusidic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Fusidic acid is combined with Raltegravir.]
[J05AF01, zidovudine, The metabolism of Raltegravir can be increased when combined with Zidovudine.]
[J05AE02, indinavir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Indinavir is combined with Raltegravir.]
[M05BA03, pamidronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Raltegravir.]
[A02BC04, rabeprazole, Rabeprazole can cause an increase in the absorption of Raltegravir resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[M05BA06, ibandronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Raltegravir.]
[M03BX01, baclofen, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Baclofen is combined with Raltegravir.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The therapeutic efficacy of Varicella zoster vaccine (live/attenuated) can be decreased when used in combination with Raltegravir.]
[A02AA05, magnesium silicate, Magnesium silicate can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A02AC02, calcium silicate, The serum concentration of Raltegravir can be decreased when it is combined with Calcium silicate.]
[L01EX05, regorafenib, The metabolism of Raltegravir can be decreased when combined with Regorafenib.]
[J05AE04, nelfinavir, The metabolism of Raltegravir can be increased when combined with Nelfinavir.]
[C08CA13, lercanidipine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lercanidipine is combined with Raltegravir.]
[G04BE03, sildenafil, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Sildenafil is combined with Raltegravir.]
[A12CC09, magnesium orotate, Magnesium orotate can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A12CC05, magnesium aspartate, Magnesium aspartate can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01EC02, dabrafenib, The metabolism of Raltegravir can be decreased when combined with Dabrafenib.]
[S03BA03, betamethasone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Betamethasone is combined with Raltegravir.]
[C10AB02, bezafibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Bezafibrate is combined with Raltegravir.]
[J05AP09, dasabuvir, The metabolism of Raltegravir can be decreased when combined with Dasabuvir.]
[A06AD03, magnesium peroxide, Magnesium peroxide can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C10AD06, acipimox, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Raltegravir is combined with Acipimox.]
[A02BC03, lansoprazole, Lansoprazole can cause an increase in the absorption of Raltegravir resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[L01CX01, trabectedin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trabectedin is combined with Raltegravir.]
[A02AB06, aloglutamol, Aloglutamol can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A02AD05, aluminum magnesium silicate, The serum concentration of Raltegravir can be decreased when it is combined with Almasilate.]
[A02AB03, aluminum phosphate, Aluminium phosphate can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C03CA02, bumetanide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Bumetanide is combined with Raltegravir.]
[M02AA03, clofezone, Rabeprazole can cause an increase in the absorption of Raltegravir resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[A12AA04, calcium carbonate, The serum concentration of Raltegravir can be decreased when it is combined with Calcium carbonate.]
[J05AE09, tipranavir, The metabolism of Raltegravir can be increased when combined with Tipranavir.]
[L04AB02, infliximab, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Raltegravir.]
[L01XX59, enasidenib, The metabolism of Raltegravir can be decreased when combined with Enasidenib.]
[A02BX12, bismuth subnitrate, The serum concentration of Raltegravir can be decreased when it is combined with Bismuth subnitrate.]
[J05AG03, efavirenz, The metabolism of Raltegravir can be increased when combined with Efavirenz.]
[A10BK04, ertugliflozin, The metabolism of Raltegravir can be decreased when combined with Ertugliflozin.]
[C09AA01, captopril, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Captopril is combined with Raltegravir.]
[N03AF01, carbamazepine, The metabolism of Raltegravir can be increased when combined with Carbamazepine.]
[H03BB01, carbimazole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Carbimazole is combined with Raltegravir.]
[B02BX09, fostamatinib, The metabolism of Raltegravir can be decreased when combined with Fostamatinib.]
[V03AE10, sodium zirconium cyclosilicate, Sodium zirconium cyclosilicate can cause an increase in the absorption of Raltegravir resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[L01EB07, dacomitinib, The metabolism of Raltegravir can be decreased when combined with Dacomitinib.]
[C10AB08, ciprofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Raltegravir is combined with Ciprofibrate.]
[C01EB09, ubidecarenone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Raltegravir is combined with Ubidecarenone.]
[A12CC06, magnesium lactate, Magnesium lactate can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01EX15, pexidartinib, The metabolism of Raltegravir can be decreased when combined with Pexidartinib.]
[J01XX09, daptomycin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Raltegravir.]
[G03AC09, desogestrel, The metabolism of Raltegravir can be increased when combined with Desogestrel.]
[J05AE05, amprenavir, The serum concentration of Raltegravir can be decreased when it is combined with Amprenavir.]
[P01BA01, chloroquine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Chloroquine is combined with Raltegravir.]
[C10AB09, etofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Raltegravir is combined with Etofibrate.]
[B03AA03, ferrous gluconate, The serum concentration of Raltegravir can be decreased when it is combined with Ferrous gluconate.]
[B03AA07, ferrous sulfate, The serum concentration of Raltegravir can be decreased when it is combined with Ferrous sulfate anhydrous.]
[A02BA01, cimetidine, Cimetidine can cause an increase in the absorption of Raltegravir resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[S03AA07, ciprofloxacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Raltegravir.]
[L01EA06, asciminib, The metabolism of Raltegravir can be decreased when combined with Asciminib.]
[C10AB01, clofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Clofibrate is combined with Raltegravir.]
[B06AX04, mitapivat, The metabolism of Raltegravir can be increased when combined with Mitapivat.]
[A02BC08, vonoprazan, Vonoprazan can cause an increase in the absorption of Raltegravir resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[M04AC01, colchicine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Colchicine is combined with Raltegravir.]
[L04AA13, leflunomide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leflunomide is combined with Raltegravir.]
[A02AD04, hydrotalcite, Hydrotalcite can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A02BC05, esomeprazole, Esomeprazole can cause an increase in the absorption of Raltegravir resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N03AX09, lamotrigine, The metabolism of Raltegravir can be increased when combined with Lamotrigine.]
[H01CA02, nafarelin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nafarelin is combined with Raltegravir.]
[A02AD02, magaldrate, Magaldrate can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A06AD01, magnesium carbonate, Magnesium carbonate can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A03AA04, mebeverine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Raltegravir is combined with Mebeverine.]
[S01XA18, cyclosporine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Raltegravir.]
[C10AA07, rosuvastatin, The risk or severity of myopathy and rhabdomyolysis can be increased when Raltegravir is combined with Rosuvastatin.]
[L01BC01, cytarabine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Raltegravir.]
[S03BA01, dexamethasone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Dexamethasone is combined with Raltegravir.]
[L01EB02, erlotinib, The metabolism of Raltegravir can be decreased when combined with Erlotinib.]
[J05AE08, atazanavir, The metabolism of Raltegravir can be decreased when combined with Atazanavir.]
[J05AE07, fosamprenavir, The serum concentration of Raltegravir can be decreased when it is combined with Fosamprenavir.]
[R03AC12, salmeterol, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Salmeterol is combined with Raltegravir.]
[C10AA01, simvastatin, The risk or severity of myopathy and rhabdomyolysis can be increased when Raltegravir is combined with Simvastatin.]
[B05XA02, sodium bicarbonate, The serum concentration of Raltegravir can be decreased when it is combined with Sodium bicarbonate.]
[D01BA02, terbinafine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Terbinafine is combined with Raltegravir.]
[P01AX02, emetine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Raltegravir is combined with Emetine.]
[N06AX14, tianeptine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Raltegravir is combined with Tianeptine.]
[C09AA02, enalapril, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Enalapril is combined with Raltegravir.]
[B05XA12, zinc chloride, Zinc chloride can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B05XA18, zinc sulfate, Zinc sulfate can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B01AC11, iloprost, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Iloprost is combined with Raltegravir.]
[N03AG01, valproic acid, The metabolism of Raltegravir can be decreased when combined with Valproic acid.]
[A02BC02, pantoprazole, Pantoprazole can cause an increase in the absorption of Raltegravir resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[C10AA04, fluvastatin, The risk or severity of myopathy and rhabdomyolysis can be increased when Raltegravir is combined with Fluvastatin.]
[L02AA03, ethinyl estradiol, The metabolism of Raltegravir can be increased when combined with Ethinylestradiol.]
[L04AD02, tacrolimus, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrolimus is combined with Raltegravir.]
[A02BA04, nizatidine, Nizatidine can cause an increase in the absorption of Raltegravir resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[L02AE02, leuprolide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Raltegravir.]
[C10AA03, pravastatin, The risk or severity of myopathy and rhabdomyolysis can be increased when Raltegravir is combined with Pravastatin.]
[M01CB01, gold sodium thiomalate, The metabolism of Raltegravir can be decreased when combined with Sodium aurothiomalate.]
[A02BA03, famotidine, Famotidine can cause an increase in the absorption of Raltegravir resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[B03AA10, ferrous ascorbate, The serum concentration of Raltegravir can be decreased when it is combined with Ferrous ascorbate.]
[L04AA40, cladribine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Raltegravir.]
[N05CD03, flunitrazepam, The metabolism of Raltegravir can be decreased when combined with Flunitrazepam.]
[V03AZ01, ethanol, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ethanol is combined with Raltegravir.]
[S01BC04, flurbiprofen, The metabolism of Raltegravir can be decreased when combined with Flurbiprofen.]
[M05BA04, alendronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Raltegravir.]
[D10AX01, aluminum chloride, Aluminum chloride can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01AD09, ganciclovir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ganciclovir is combined with Raltegravir.]
[C10AB04, gemfibrozil, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Gemfibrozil is combined with Raltegravir.]
[A12AA13, calcium citrate, The serum concentration of Raltegravir can be decreased when it is combined with Calcium citrate.]
[L01EX02, sorafenib, The metabolism of Raltegravir can be decreased when combined with Sorafenib.]
[B05CB03, magnesium citrate, Magnesium citrate can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A12CC03, magnesium gluconate, Magnesium gluconate can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01XA07, aluminum potassium sulfate, Potassium alum can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J04AB04, rifabutin, The serum concentration of Raltegravir can be decreased when it is combined with Rifabutin.]
[M05BA07, risedronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Risedronic acid is combined with Raltegravir.]
[L01CD01, paclitaxel, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Paclitaxel is combined with Raltegravir.]
[S01BC01, indomethacin, The metabolism of Raltegravir can be decreased when combined with Indomethacin.]
[A16AX05, zinc acetate, Zinc acetate can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A12CB02, zinc gluconate, Zinc gluconate can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C10AA06, cerivastatin, The risk or severity of myopathy and rhabdomyolysis can be increased when Raltegravir is combined with Cerivastatin.]
[V03AB01, ipecac, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Raltegravir is combined with Ipecac.]
[J05AF04, stavudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Stavudine is combined with Raltegravir.]
[J04AC01, isoniazid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Isoniazid is combined with Raltegravir.]
[D10BA01, isotretinoin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Isotretinoin is combined with Raltegravir.]
[P02CF01, ivermectin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ivermectin is combined with Raltegravir.]
[A07BC02, kaolin, Kaolin can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[H01AC01, somatropin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Raltegravir.]
[A02AB01, aluminum hydroxide, Aluminum hydroxide can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J02AB02, ketoconazole, The metabolism of Raltegravir can be decreased when combined with Ketoconazole.]
[V03AC03, deferasirox, The metabolism of Raltegravir can be decreased when combined with Deferasirox.]
[D10AX04, aluminum oxide, Aluminum oxide can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C10AA02, lovastatin, The risk or severity of myopathy and rhabdomyolysis can be increased when Raltegravir is combined with Lovastatin.]
[B05XA11, magnesium chloride, Magnesium chloride can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[G04BX01, magnesium hydroxide, Magnesium hydroxide can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A12CC10, magnesium oxide, Magnesium oxide can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V04CC02, magnesium sulfate, Magnesium sulfate can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01EA03, nilotinib, The metabolism of Raltegravir can be decreased when combined with Nilotinib.]
[P01BC02, mefloquine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Mefloquine is combined with Raltegravir.]
[A03AB07, methantheline, Methantheline can cause an increase in the absorption of Raltegravir resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[L04AX03, methotrexate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Methotrexate is combined with Raltegravir.]
[C02AB01, methyldopa, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Methyldopa is combined with Raltegravir.]
[A03FA01, metoclopramide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Metoclopramide is combined with Raltegravir.]
[J01AA08, minocycline, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Minocycline is combined with Raltegravir.]
[C01BD01, amiodarone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amiodarone is combined with Raltegravir.]
[N06AA09, amitriptyline, The metabolism of Raltegravir can be decreased when combined with Amitriptyline.]
[B02BX05, eltrombopag, The metabolism of Raltegravir can be decreased when combined with Eltrombopag.]
[L01EX03, pazopanib, The metabolism of Raltegravir can be decreased when combined with Pazopanib.]
[N07BB04, naltrexone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Raltegravir.]
[L01CD02, docetaxel, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Docetaxel is combined with Raltegravir.]
[L02BG04, letrozole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Letrozole is combined with Raltegravir.]
[J02AA01, amphotericin B, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Raltegravir.]
[C10AD02, niacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Niacin is combined with Raltegravir.]
[S01AE02, norfloxacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Norfloxacin is combined with Raltegravir.]
[S02AA16, ofloxacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ofloxacin is combined with Raltegravir.]
[A02BC01, omeprazole, Omeprazole can cause an increase in the absorption of Raltegravir resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[M01CC01, penicillamine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Penicillamine is combined with Raltegravir.]
[N03AA02, phenobarbital, The metabolism of Raltegravir can be increased when combined with Phenobarbital.]
[A02BC06, dexlansoprazole, Dexlansoprazole can cause an increase in the absorption of Raltegravir resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N03AB02, phenytoin, The metabolism of Raltegravir can be increased when combined with Phenytoin.]
[C10AA05, atorvastatin, The risk or severity of myopathy and rhabdomyolysis can be increased when Raltegravir is combined with Atorvastatin.]
[J05AE01, saquinavir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Saquinavir is combined with Raltegravir.]
[C09CA02, eprosartan, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Eprosartan is combined with Raltegravir.]
[J05AE03, ritonavir, The metabolism of Raltegravir can be increased when combined with Ritonavir.]
[C10AA08, pitavastatin, The risk or severity of myopathy and rhabdomyolysis can be increased when Raltegravir is combined with Pitavastatin.]
[N03AA03, primidone, The metabolism of Raltegravir can be increased when combined with Primidone.]
[M04AB01, probenecid, The metabolism of Raltegravir can be decreased when combined with Probenecid.]
[C01BA02, procainamide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Procainamide is combined with Raltegravir.]
[L01XB01, procarbazine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Procarbazine is combined with Raltegravir.]
[C10AB05, fenofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Fenofibrate is combined with Raltegravir.]
[N01AX10, propofol, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propofol is combined with Raltegravir.]
[H03BA02, propylthiouracil, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Raltegravir.]
[R03DC03, montelukast, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Montelukast is combined with Raltegravir.]
[A02BA02, ranitidine, Ranitidine can cause an increase in the absorption of Raltegravir resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[J04AB02, rifampin, The serum concentration of Raltegravir can be decreased when it is combined with Rifampicin.]
